Folate receptor alpha, a cell-surface protein long exploited as a delivery target in epithelial ovarian cancer, is emerging as a far more consequential player in the earliest and most ambiguous corners of ovarian tumorigenesis. A new retrospective study of 100 surgically resected ovarian epithelial tumors has found that high expression of folate receptor alpha, commonly abbreviated FRα or FOLR1, is tightly linked to tumor recurrence and to an immunosuppressive tumor microenvironment in borderline ovarian tumors and low-grade serous ovarian carcinoma, two entities that occupy a diagnostic and prognostic gray zone in gynecologic pathology. The findings, published as an open-access research article in the Journal of Ovarian Research, suggest that a biomarker already validated in high-grade serous ovarian cancer may also help clinicians identify which patients with seemingly indolent tumors are quietly at risk of relapse.
The research team, led by corresponding author Wenjun Cheng of the Department of Gynecology at Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, with first authors Xun Xu of Nanjing Medical University and Lin Yuan of Jiangsu Province Hospital contributing equally, analyzed tumor specimens collected between 2014 and 2024. The cohort comprised 91 borderline ovarian tumors and 9 low-grade serous ovarian carcinomas, a distribution that reflects the clinical reality that frank carcinomas at the low-grade end of the serous spectrum are comparatively rare, and that borderline tumors dominate the surgical pathology of early, atypical ovarian epithelial proliferations. All patients underwent surgical resection, allowing the investigators to correlate molecular and immunologic features measured directly in resected tissue with downstream clinical outcomes such as recurrence and disease-free survival.
FRα is a glycosylated folate-binding protein anchored to the cell surface by a glycosylphosphatidylinositol moiety, and its biology makes it unusually attractive as both a biomarker and a drug target. Because the receptor binds folic acid with high affinity and is minimally expressed in most normal adult tissues while being overexpressed in a majority of epithelial ovarian carcinomas, it has become the backbone of several targeted strategies, including antibody-drug conjugates such as mirvetuximab soravtansine, radioligand therapies, and folate-conjugated nanoparticles designed to ferry cytotoxic payloads selectively into tumor cells. But the receptor’s expression pattern in borderline ovarian tumors, which are not frankly invasive malignancies, and in low-grade serous ovarian carcinoma, which follows a distinct molecular pathway dominated by MAPK pathway mutations rather than the TP53-driven catastrophe seen in high-grade disease, had remained poorly characterized. The new study set out to close that gap, asking not only how often FRα is expressed across histologic subtypes but also whether its expression carries prognostic weight and shapes the local immune landscape.
The answer to the first question is nuanced. Using immunohistochemistry with an immunoreactive score threshold of 8 or higher to define high expression, the investigators found that only 13 percent of the entire cohort, 13 of 100 tumors, qualified as FRα-high. Expression was strikingly heterogeneous across histologic subtypes, but it concentrated in the serous lineage: within the 77 serous tumors, 12 cases, or 15.6 percent, showed high FRα expression. Serous borderline tumors that displayed micropapillary features, a morphology pathologists regard as an intermediate step on the transformation pathway from benign proliferation to invasive low-grade carcinoma, expressed FRα at levels approaching those seen in frank low-grade serous carcinomas. This graded pattern of expression along the recognized spectrum of serous tumor progression is biologically telling. It implies that FRα upregulation is not a random epiphenomenon but is acquired, or at least amplified, as serous tumors acquire more aggressive architectural features, positioning the receptor as a potential molecular readout of malignant progression within the borderline category.
The prognostic data are the study’s most clinically arresting contribution. Tumors classified as FRα-high recurred at a rate of 42 percent, compared with just 14 percent among FRα-low tumors, a nearly threefold difference that reached statistical significance at P equal to 0.003. The association was particularly pronounced within the serous subset, where borderline tumors with micropapillary architecture and high FRα expression behaved in a manner much closer to true carcinomas than to their benign-appearing counterparts. For a group of tumors whose management often hinges on the delicate balance between fertility-sparing surgery and more radical intervention, the ability to flag, at the time of initial pathology, which lesions carry a meaningful recurrence risk could meaningfully change surveillance intensity and surgical decision-making. A young woman with a serous borderline tumor and high FRα expression might warrant closer follow-up and a lower threshold for completion surgery, while an FRα-low tumor could support a more conservative course.
Beyond prognosis, the study delved into the tumor immune microenvironment using multiplex immunofluorescence, a technique that allows simultaneous visualization of multiple protein markers on a single tissue section and thereby permits single-cell-level mapping of which cell populations express which molecules. The results painted a coherent and rather sobering picture. FRα expression was inversely correlated with immune cell infiltration, meaning that the most FRα-rich tumors were also the most immunologically cold, a configuration classically associated with poor responsiveness to immunotherapy and with mechanisms of immune escape. At the same time, FRα expression was positively correlated with expression of both PD-L1, the immune checkpoint ligand that tumors use to suppress cytotoxic T cells, and PD-1, its receptor on immune cells. The correlation coefficient between FRα and PD-L1 was 0.36, with a P value below 0.001, indicating a statistically robust association across the cohort.
The most refined analysis focused on the fraction of tumor epithelial cells co-expressing both FRα and PD-L1 on their surface. In serous tumors, a high proportion of these FRα-positive PD-L1-positive double-positive cells was significantly associated with shorter disease-free survival. This double-positive phenotype is functionally provocative. It suggests that the very cells bearing the folate receptor, the cells that would be preferentially targeted by FRα-directed therapies, are also the cells most actively engaged in negotiating immune evasion through the PD-1/PD-L1 axis. In other words, FRα-high tumors may not merely be biologically aggressive in a cell-autonomous sense; they may also be constructing a microenvironment in which antitumor immunity is locally disarmed. The inverse relationship between FRα and immune infiltration reinforces this interpretation, sketching a model in which FRα-high serous tumors combine intrinsic recurrence-prone behavior with an immunosuppressive shield.
These observations carry tangible therapeutic implications. If FRα-high borderline tumors and low-grade serous carcinomas also tend to be PD-L1-positive, then FRα-targeted agents and immune checkpoint inhibitors might be rationally combined in this subgroup, with the folate receptor serving as a tumor-selective delivery address and checkpoint blockade releasing the local T-cell brake. Conversely, the finding that FRα-high tumors are immune-cold and infiltrate-poor tempers expectations: checkpoint monotherapy works best in inflamed tumors, and the FRα-high phenotype described here may require strategies that first induce immune infiltration, such as chemotherapy, radiotherapy, or STING-agonist approaches, before checkpoint inhibition can be effective. The study also raises the possibility of using FRα as a patient-selection biomarker in future clinical trials, an approach already under exploration in high-grade serous ovarian cancer but not previously grounded in data from the borderline and low-grade setting.
The study’s methodology deserves attention for what it accomplishes within its retrospective frame. By combining conventional immunohistochemistry with an immunoreactive scoring system, multiplex immunofluorescence for immune markers, and linkage to a decade of surgical outcomes, the investigators were able to integrate pathology, molecular biology, and clinical follow-up into a single analytical framework. The inclusion of tumors spanning the full morphologic spectrum from typical serous borderline tumors through micropapillary variants to low-grade serous carcinomas allowed the team to detect the graded increase in FRα expression along the progression axis, a finding that would have been invisible had the cohort been restricted to a single diagnostic category. The work was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and conducted in accordance with the Declaration of Helsinki, with informed consent waived given the retrospective design, and the authors declare no competing interests. Funding came from multiple Chinese sources, including the National Natural Science Foundation of China and the Natural Science Fund of Jiangsu Province.
Limitations remain. The cohort is modest, particularly the nine low-grade serous carcinomas, and the retrospective single-institution design means that the findings require validation in larger, multi-center, ideally prospective series before FRα immunostaining becomes standard practice in the evaluation of borderline tumors. Nevertheless, the convergence of three independent signals, the graded expression along the serous progression pathway, the strong association with recurrence, and the linkage to an immunosuppressive microenvironment, gives the results considerable internal consistency. If validated, routine FRα and PD-L1 testing on resected borderline and low-grade serous tumors could become an inexpensive, widely deployable risk-stratification tool, guiding follow-up intensity, informing surgical extent, and identifying patients for whom FRα-directed therapeutics, alone or in combination with immunotherapy, might alter the natural history of a disease that has long been underestimated. For a receptor first celebrated as a molecular mailbox for drug delivery, folate receptor alpha may turn out to be equally valuable as a molecular signpost, pointing clinicians toward the borderline tumors that are quietly preparing to misbehave.
Subject of Research: Folate receptor alpha (FRα) expression and its prognostic and immune microenvironmental associations in borderline ovarian tumors and low-grade serous ovarian carcinoma
Subject of Research: Medicine
Article Title: FRα expression in borderline ovarian tumors and low-grade serous ovarian carcinoma: prognostic and immune microenvironmental associations
Article References: Xu, X., Yuan, L., Meng, H., Zhang, L., & Cheng, W. (2026). FRα expression in borderline ovarian tumors and low-grade serous ovarian carcinoma: prognostic and immune microenvironmental associations. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02195-7
Image Credits: AI Generated
DOI: 10.1186/s13048-026-02195-7
Keywords: borderline ovarian tumor, folate receptor alpha, PD-L1, tumor immune microenvironment, recurrence, multiplex immunofluorescence, low-grade serous ovarian carcinoma
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 11, 2026). Folate receptor alpha ties prognosis and immune landscape in ovarian tumors. Scienmag. https://scienmag.com/folate-receptor-alpha-ties-prognosis-and-immune-landscape-in-ovarian-tumors/
Nathaniel Bowman. “Folate receptor alpha ties prognosis and immune landscape in ovarian tumors.” Scienmag, 11 September 2026, https://scienmag.com/folate-receptor-alpha-ties-prognosis-and-immune-landscape-in-ovarian-tumors/. Accessed 11 September 2026.
Nathaniel Bowman. “Folate receptor alpha ties prognosis and immune landscape in ovarian tumors.” Scienmag. September 11, 2026. https://scienmag.com/folate-receptor-alpha-ties-prognosis-and-immune-landscape-in-ovarian-tumors/
Copy citation Download RIS
Tags: Biomarker identification in borderline ovarian tumorsdiagnostic challenges in borderline ovarian tumorsfolate receptor alpha as a biomarker for ovarian cancer recurrenceFolate receptor alpha as an immune microenvironment markerFolate receptor alpha expression in early ovarian tumorigenesisFolate receptor alpha in ovarian tumor prognosisFOLR1 as a therapeutic target in ovarian cancerimmune landscape of low-grade serous ovarian carcinomaimmune microenvironment in borderline ovarian tumorsImmunosuppressive tumor microenvironment in ovarian tumorsimplications of folprognostic significance of folate receptor alpha in ovarian cancerretrospective analysis of ovarian epithelial tumorsrole of FOLR1 expression in ovarian tumor progressionRole of FOLR1 in low-grade serous ovarian carcinomatumor microenvironment and immunosuppression in ovarian tumorstumor recurrence prediction in ovarian cancer
